Amyris Inc. (NASDAQ:AMRS) has announced encouraging initial data in the pre-clinical trial of the ribonucleic acid (RNA) COVID-19 vaccine platform. The company also released promising information regarding its potential to address manufacturing and supply scale up as well as distribution and refrigerated storage challenges.
Amyris COVID-19 program shows enhanced efficacy
In October 2020, the company announced collaboration and exclusive license agreement with Infectious Disease Research Institute (IDRI) I advancing proprietary RNA vaccine platform. The deal included the development of a potential COVID-19 vaccine. According to initial pre-clinical trial data, IDRI’s Nanostructured Lipid Carrier (NLC) vaccine platform has shown enhanced antibody production levels against the SARS-2-CoV protein using the self-adjuvanting RNA vaccine. Most importantly, the results were consistent with similar data from Pfizer/BioNTech and Moderna on their corresponding mRNA vaccines. The IDRI/Amyris platform plans to advance to phase 1 clinical study with support from the Portuguese government and partnerships.
John Melo, the company’s CEO and President indicated that RNA tech is the future of vaccines. He said that there is a need for a second-generation COVID-19 vaccine to solve the current manufacturing scale-up and supply chain challenges and enhance accessibility and deployment globally. Melo said there is a need for a quick response to the pandemic, with tech that can address the current COVID-19 crisis and emerging variants.
Amyris releases promising results of its acne formulation
The company recently announced breakthrough results of its early clinical study of the fermentation-based ingredients clean topical formulations for acne treatment. Princeton Consumer Research Corp (PCR) conducted the acne formulations study that comprised two clean fermentation-based ingredients and showed enhanced efficacy relative to ten other standard acne treatments available in the US. The study measured efficacy relative to acne reduction magnitude and time is taken to be effective.
Melo said that they are delighted with the preliminary clinical study results that showed the company’s science power in addressing skincare issues. He said that the company is looking forward to finalizing the novel acne formulation and prepare for an accelerated consumer launch.